🦠Understanding Helicobacter pylori treatment patterns across Europe is essential for improving gastric cancer prevention strategies. Our partner Hp-Eureg (The European Registry on H. pylori Management) has published two insightful open-access articles that explore how H. pylori is managed in different healthcare settings: 📌 Czech Republic – A look at first-line empirical treatment approaches between 2019–2024: 🔗 https://lnkd.in/erQHaPi3 📌 Azerbaijan – A look at first-line empirical prescriptions between 2020–2023: 🔗 https://lnkd.in/e2RekfaJ) These publications highlight the real-world diversity in managing H. pylori. An important contributor to gastric cancer, which demonstrates the need for tailored, evidence-based prevention strategies. ✨ Thank you to the team at Hp-EuReg for advancing the knowledge that fuels TOGAS’s mission! Olga P. Nyssen Colm O'Morain Lumír Kunovský Sabina Hrubá Jakub Langner Česká gastroenterologická společnost ČLS JEP
It is a pity that the triple PPI + amoxicillin + clarithromycin regimen is still very often used, probably without prior testing of all strains for clarithromycin susceptibility.